Medical Disclaimer: We are not doctors. The content in this video is for educational and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Any compounds discussed may be intended for research purposes only. Use at your own risk.Welcome back, warriors! In this episode of Peptide of the Week, JD Denham and William T. Haas sit down with peptide expert, keynote speaker, and industry insider Paul Bakhtiar to break down what’s really happening behind the scenes in the peptide industry.From the sudden shutdown of Peptide Sciences to upcoming regulatory changes and the future of GLP-1 compounds like Retatrutide, this episode dives deep into the evolving landscape of peptides and what it could mean for consumers moving forward.Paul shares insider knowledge on banking issues, regulatory pressure, pharmaceutical influence, and how education and consumer demand are helping push peptides further into mainstream medicine.Chapters:00:00 – Intro & Paul Bakhtiar Returns03:15 – Peptide Sciences Shutdown08:37 – Peptide Regulations Changing11:27 – Telehealth vs Research Peptides13:33 – Retatrutide & Big Pharma Control21:11 – Peptides Returning to Compounding27:31 – Doctors Learning About Peptides32:43 – New Peptide FLGR-2437:48 – Paul’s Personal Peptide Stack39:31 – Dihexa & Brain Health45:09 – Peptides vs Steroids47:48 – Teen Athletes & Peptide Use52:04 – Thymosin Alpha-1 & Cancer Research54:00 – Warrior Platform AnnouncementWe cover:🏛 What actually happened to Peptide Sciences– The sudden shutdown that shocked the peptide community– Alleged issues with offshore credit card processing– Why it likely had nothing to do with peptides themselves– How banking restrictions affect peptide companies💳 Why peptide companies struggle with payment processors– Banks labeling peptide businesses “high risk”– Why companies rely on ACH, Zelle, crypto, and other payment systems– How frozen reserves and chargeback policies impact companies– Why payment limitations are common across the peptide industry⚖️ New regulatory shifts in the peptide world– 14–19 peptides potentially moving into Category 1 compounding– What this means for doctors and compounding pharmacies– How prescription access could change availability and pricing– The difference between FDA approval and compounding eligibility💉 Retatrutide and the GLP-1 landscape– Why Retatrutide is projected to be a trillion-dollar compound– Eli Lilly’s push toward full FDA approval– How pharmaceutical monopolies affect peptide availability– Why research peptide access may shrink as drugs move through approval🧬 Why peptides aren’t always FDA approved– Lack of profit incentive for pharmaceutical companies– High cost of clinical trials and approval processes– Why many effective compounds remain outside the approval pipeline– How consumer demand is forcing the medical world to pay attention🧠 The growing peptide movement– Why patients are bringing peptide discussions to their doctors– How education and podcasts are helping drive awareness– Why more physicians are starting to research peptides themselves– The shift toward preventative and regenerative health💡 The big takeaway: peptides are rapidly evolving, and the demand for these signaling molecules continues to grow as more people discover their potential for healing, longevity, and performance.As regulation changes and pharmaceutical companies move deeper into the space, access may shift but education and consumer awareness are pushing the peptide movement forward.📺 Subscribe for more no-fluff peptide education every week.Follow Paul Bakhtiar:Instagram: https://www.instagram.com/paulbakhtiar/Follow us on social media:JD's Instagram: https://www.instagram.com/jd_denham_fitWill's Instagram: https://www.instagram.com/williamthaas/Warrior-Makers page: https://www.instagram.com/warrior_makers_supplements/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related